• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Medicare reform law carries hidden costs

Author(s):

Bob Gatty

While Medicare recipients now have some help in covering the cost of prescription drugs, the new Medicare reform law passed by Congress carries some hidden costs that may result in difficulties in obtaining care for some patients. This applies, in particular, to physicians who administer drugs in their offices.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
2024 Drug Approvals in Review: Part 1
December 26th 2024

2024 Drug Approvals in Review: Part 1

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Dermatology Times 2024 in Review: Psoriasis
December 26th 2024

Dermatology Times 2024 in Review: Psoriasis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Phase 3 Trials Confirm Deucravacitinib’s Efficacy in PsA
December 24th 2024

Phase 3 Trials Confirm Deucravacitinib’s Efficacy in PsA

Derm In The News: 2024
December 24th 2024

Derm In The News: 2024

© 2024 MJH Life Sciences

All rights reserved.